Advertisement

Topics

Antisense Pharma GmbH Company Profile

08:56 EST 20th November 2017 | BioPortfolio

ANTISENSE PHARMA is an innovative biotech company aimed at developing and marketing novel antisense technology based drugs for the treatment of cancer and other so far incurable diseases.
Founded in Göttingen 1998, the company is now headquartered in the BioPark in Regensburg, one of the most prominent Biotech centers in Germany. ANTISENSE PHARMA is run by corporate executives with a strong track record in both scientific expertise and entrepreneurial biotechnology. They are supported by a highly professional staff with a strong pharmaceutical as well as clinical background and experience in business.
ANTISENSE PHARMA develops antisense drugs that specifically block the production of key proteins responsible for the onset and progression of diseases such as cancer. This approach represents a novel therapeutic modality by which diseases are rather tackled directly at their pathogenic cause than by merely combating their effects. Antisense Pharma drugs are specifically targeted at pre-selected proteins such as TGF-beta. Thus the company`s approach is unique in the field of antisense drug development.
The lead product of ANTISENSE PHARMA is AP 12009. It has been developed to activate the body’s own immune system against highly malignant tumors. It currently is in an advanced stage of clinical testing. A solid international patent portfolio includes this drug and further candidate antisense compounds as well as various target proteins.

Location

Ms Ursula Dalferth-BayreutherJosef-Engert-Str. 9
Regensburg
93053
Germany

Contact

Phone: 49-941-9201-30
Fax: 49-941-9201 329
Email: info@antisense-pharma.com


News Articles [733 Associated News Articles listed on BioPortfolio]

The Growing Importance of Antisense Oligonucleotides in Alzheimer’s Research

ArticleThere is now renewed interest in alternative treatments based on short chains of nucleic acids known as antisense oligonucleotides, with recent findings suggesting that antisense treatment may ...

GSK walks away from Ionis antisense drugs

GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.

Ionis licenses antisense drug to Janssen

Ionis Pharmaceuticals has earned $5m license fee from Janssen Biotech for a second orally delivered Generation 2.5 antisense drug.

Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides

A scalable chemical method to control phosphorothioate chirality demonstrates its impact on the efficacy of antisense oligonucleotides.

Trial shows safety and tolerability of antisense oligomer for treatment of influenza A

A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen -- an antisense oligomer that inhibits the production of certain influenza proteins -- is safe ...

Körber Plans Takeover of Systec Services GmbH

     (Photo: http://mma.prnewswire.com/media/558312/SystecServices_Headquarters.jpg) With the planned takeover, Körber Medipak Systems GmbH, the holding company of Business Area Pharma Systems...

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 17102017] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 12062017] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

PubMed Articles [135 Associated PubMed Articles listed on BioPortfolio]

Novel stress-inducible antisense RNAs of protein-coding loci are synthesized by RNA-dependent RNA polymerase.

Our previous study identified approximately 6,000 abiotic stress-responsive non-coding transcripts existing on the antisense strand of protein-coding genes, and implied that a type of antisense RNA wa...

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Intracerebroventricular Delivery in Mice for Motor Neuron Diseases.

The use of antisense oligonucleotides to target specific mRNA sequences represents a promising therapeutic strategy for neurological disorders. Recent advances in antisense technology enclose the deve...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Targeting Functional Noncoding RNAs.

Noncoding RNAs have essential biochemical functions in different areas of cellular metabolism, including protein synthesis, RNA splicing, protein secretion, and DNA replication. We have successfully u...

Clinical Trials [136 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

AEG35156 is a second generation antisense which targets XIAP mRNA to lower XIAP levels and the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemo...

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

The Epidermal Growth Factor Receptor (EGFR) is highly expressed in SCCHN and its overexpression is associated with poor patient outcome. EGFR is a promising target of anticancer therapy. W...

Clinical Trial of L-Grb-2 Antisense Oligonucleotide in CML, AML, ALL & MDS

The goal of this clinical research study is to find the highest safe dose of a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS) that can be given...

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects

The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics

Companies [1240 Associated Companies listed on BioPortfolio]

Antisense Pharma GmbH

ANTISENSE PHARMA is an innovative biotech company aimed at developing and marketing novel antisense technology based drugs for the treatment of cancer and other so far incurable diseases.Founded in G...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

INJEX Pharma AG

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the m...

CROMA-PHARMA GmbH

CROMA-PHARMA is a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology...

Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-b...

More Information about "Antisense Pharma GmbH" on BioPortfolio

We have published hundreds of Antisense Pharma GmbH news stories on BioPortfolio along with dozens of Antisense Pharma GmbH Clinical Trials and PubMed Articles about Antisense Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Antisense Pharma GmbH Companies in our database. You can also find out about relevant Antisense Pharma GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record